Company intelligence / Profile preview

Hangzhou NeoVax Biotechnology

Hangzhou, Zhejiang, Chinasigma.larvol.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The lead program, NPVAC-2 (NeoPep Vaccine), is under Phase 1 clinical evaluation for glioma. Early results indicate safety and preliminary signals of efficacy. Approximately 80 patients have been treated in investigator-initiated trials, with results published in international journals[3][5][2].

Therapeutic areas: OncologyNeurology
Modalities: Personalized antigen vaccineTherapeutic vaccinePeptides
Industry: Biotech

Drug pipeline

2 assets

NeoPep Vaccine1

Phase 1

Indications: Glioblastoma

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hangzhou NeoVax Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou NeoVax Biotechnology.

Explore the full profile